Literature DB >> 8390748

Defect in entry and altered pathogenicity of a polyoma virus mutant blocked in VP2 myristylation.

R Sahli1, R Freund, T Dubensky, R Garcea, R Bronson, T Benjamin.   

Abstract

We have examined effects of mutations of the minor capsid proteins VP2 and VP3 of polyoma virus. Infection of cells by mutants blocked in expression of either VP2 or VP3 by alterations of their initiator methionine codons led to the rapid selection of wild-type revertants. This reversion suggests a strong, if not absolute, requirement for both proteins in virus growth. A mutant virus, VP2*, in which alanine was substituted for glycine-2, expressed a nonmyristylated form of VP2 that was incorporated into virions. Studies of VP2* revealed a 15- to 20-fold lower specific infectivity and a delay in growth in both primary and established mouse cells compared to wild-type virus. Analysis of the growth delay indicated a defect in an early step of infection, at or prior to uncoating. Synthesis of viral DNA and VP1 was delayed by about 9 hr in mutant compared to that in wild-type infected cells. No evidence was obtained for an effect on either virus assembly (encapsidation) or stability of virions. Infection of mice by the VP2* mutant virus resulted in attenuated virus replication and tumor induction which were much more severely affected following intranasal inoculation than intraperitoneal inoculation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390748     DOI: 10.1006/viro.1993.1016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Chromosome-protein interactions in polyomavirus virions.

Authors:  Mariarosaria Carbone; Giuseppe Ascione; Silvia Chichiarelli; Marie-Isabelle Garcia; Margherita Eufemi; Paolo Amati
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Identification of amino acid residues within simian virus 40 capsid proteins Vp1, Vp2, and Vp3 that are required for their interaction and for viral infection.

Authors:  Akira Nakanishi; Akiko Nakamura; Robert Liddington; Harumi Kasamatsu
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  JC virus minor capsid proteins Vp2 and Vp3 are essential for virus propagation.

Authors:  M L Gasparovic; G V Gee; W J Atwood
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

4.  Requirements for the formation of membrane pores by the reovirus myristoylated micro1N peptide.

Authors:  Lan Zhang; Melina A Agosto; Tijana Ivanovic; David S King; Max L Nibert; Stephen C Harrison
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

5.  Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry.

Authors:  X S Chen; T Stehle; S C Harrison
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 6.  Principles of polyoma- and papillomavirus uncoating.

Authors:  Carla Cerqueira; Mario Schelhaas
Journal:  Med Microbiol Immunol       Date:  2012-09-23       Impact factor: 3.402

7.  Murine polyomavirus requires the endoplasmic reticulum protein Derlin-2 to initiate infection.

Authors:  Brendan N Lilley; Joanna M Gilbert; Hidde L Ploegh; Thomas L Benjamin
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Expression of the polyomavirus minor capsid proteins VP2 and VP3 in Escherichia coli: in vitro interactions with recombinant VP1 capsomeres.

Authors:  S E Delos; T P Cripe; A D Leavitt; H Greisman; R L Garcea
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

9.  Polyomavirus VP1 phosphorylation: coexpression with the VP2 capsid protein modulates VP1 phosphorylation in Sf9 insect cells.

Authors:  M Li; S E Delos; L Montross; R L Garcea
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly.

Authors:  M P Ravanello; D E Hruby
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.